Trial Profile
To evaluate the association between UGT1A1 gene promoter polymorphism and hyperbilirubinemia in Korean chronic myeloid leukemia patients treated with Nilotinib and Radotinib as a frontline therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Radotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 04 Aug 2015 New trial record
- 14 Jun 2015 Results (n=94) presented at the 20th Congress of the European Haematology Association.